COMMUNIQUÉS West-GlobeNewswire

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

15/06/2017 - 22:30

AMF REGULATED INFORMATION Montrouge, France, June 15, 2017 DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting Shareholders approve all proposed resolutions DBV Technologies ( [...]

NANOBIOTIX a présenté de nouvelles données translationnelles lors du workshop d'Immunothérapie organisé par l'ASTRO, le NCI et le SITC

15/06/2017 - 21:43

NANOBIOTIX A PRESENTE DE NOUVELLES DONNEES TRANSLATIONNELLES LORS DU WORKSHOP D'IMMUNOTHERAPIE ORGANISE PAR L'ASTRO, LE NCI ET LE SITC Données translationelles montrant une activation du système immunitaire contre les [...]

NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop

15/06/2017 - 21:43

NANOBIOTIX: NEW TRANSLATIONAL DATA PRESENTED AT ASTRO, NCI AND SITC'S IMMUNOTHERAPY WORKSHOP Translational data showing tumor immune activity and positive Tumor Infiltrating Lymphocytes (TILs) in human and mouse model [...]

FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®

15/06/2017 - 20:00

FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus ® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicine Sandoz looks [...]

Solon Eiendom ASA - Primary insider notification

15/06/2017 - 18:02

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 15 June 2017) Solon Eiendom ASA Board member Edvin Austbø (through his wholly owned company Alden AS) has [...]

Nestlé to explore strategic options for its US confectionery business

15/06/2017 - 18:02

This press release is also available in Français (pdf) and Deutsch (pdf) ....................................... Vevey, 15 June 2017 Nestlé to explore strategic options for its US confectionery business Nestlé will [...]

Solon Eiendom ASA - Primary insider notification

15/06/2017 - 17:59

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 15 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company [...]

Participation de Nicox à la Convention Internationale BIO 2017

15/06/2017 - 17:45

Participation de Nicox à la Convention Internationale BIO 2017 15 juin 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale de Recherche et [...]

Nicox to present at the 2017 BIO International Convention

15/06/2017 - 17:45

Nicox to present at the 2017 BIO International Convention June 15, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Emmet [...]

ThromboGenics Long-time Non-executive Director Thomas Clay Appointed Chairman of the Board of Directors

15/06/2017 - 17:40

Leuven, Belgium, 15 June 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announces that the Board has appointed long-time non-executive [...]

Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of vested restricted stock units

15/06/2017 - 15:09

Lars Lund-Roland, member of the Board of Targovax ASA, has on 15 June 2017 subscribed for 16,394 shares in Targovax ASA at a price of NOK 0.10 per share in connection with settlement of vested restricted stock units (" [...]

RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection

15/06/2017 - 14:00

Subject to a successful outcome and any additional regulatory feedback, the confirmatory Phase III study (ERADICATE Hp 2) is expected to complete the package required for a potential U.S. NDA for RHB-105, newly branded [...]

Summit Therapeutics to Participate in JMP Securities Life Sciences Conference

15/06/2017 - 13:00

Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 15 June 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug [...]

uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies

15/06/2017 - 13:00

-- Study published in Molecular Therapy provides proof of concept of successful cross-administration of AAV5- and AAV1-based gene therapies -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 15, 2017 (GLOBE [...]

NCSBN CEO Benton Receives Great Cross of Spanish Nursing from the Spanish General Council of Nursing

15/06/2017 - 12:00

CHICAGO, June 15, 2017 (GLOBE NEWSWIRE) -- NCSBN CEO David Benton, RGN, PhD, FFNF, FRCN, FAAN, received the Great Cross of Spanish Nursing in the Gold Category from the Spanish General Council of Nursing in Barcelona, [...]

Pöyry and Betulium sign co-operation agreement to unlock full value chain benefits for clients in bio-based businesses

15/06/2017 - 11:00

Pöyry and Betulium have signed a Letter of Intent (LOI) for co-operation that will enable both companies to serve their clients better in bio-based businesses. Pöyry and Betulium share common objectives in bioindustry: [...]

Zealand increases its share capital as a consequence of exercise of employee warrants

15/06/2017 - 10:11

Copenhagen, June 15, 2017 - Zealand Pharma ("Zealand") has increased its share capital by a nominal amount of DKK 8,537 divided into 8,537 new shares with a nominal value of DKK 1 each. The increase is a consequence of [...]

ESPERITE (ESP): L1 Capital subscribes to the third packed tranche of investment today

15/06/2017 - 07:17

Zutphen, The Netherlands, 15 June 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a third Packed Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]

Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years

15/06/2017 - 07:15

Cosentyx ® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] Additional data show rapid and sustained pain [...]